Sonnet Biotherapeutics, Inc.:
Sonnet is utilizing a platform approach to develop immuno-oncology therapeutics featuring a proprietary fully human “Albumin Binding Domain” (ABD) capable of linking 1-2 different therapeutic targets. Sonnet's interleukin-based candidate has been shown to enhance pK (up to 10 fold) and improve tumor delivery with an increase in in vivo efficacy (30 fold) as demonstrated in a mice tumor model. The Sonnet platform de-risks the use of interleukins by greatly extending their in vivo half-life, while also improving their specificity to tumor tissue.
US - Middle Atlantic
Phase l or ll
Central Nervous System
100 Overlook Center
Princeton, NJ 08540
Top 10 Holders of Sonnet BioTherapeutics Holdings, Inc Units Cons of 1 Pfd Series 1 + 1 Wt 29.12.23
Top 10 Holders of Sonnet BioTherapeutics Holdings, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by